Our San Diego location hosts the following teams - Laboratory Operations, Facilities, Technology, TOCR, Research and Development (Early Research and Assay Development), Medical, and Legal teams. Client Services and other teams will be there as well soon.
|Senior Scientist I, Early Research & Development||Research and Early Development||100377||San Diego||California||United States||San Diego, California, United States||Research and Early Development||About the Job The Senior Scientist , Molecular Biology & Sequencing is part of the Research and Early Development team in FMI’s Product Development group. This position explores new technologies and biomarker candidates to address unmet needs...|
|Sr Automation Engineer||Assay Development||100373||San Diego||California||United States||San Diego, California, United States||Assay Development||About the Job The Senior Automation Engineer is responsible for automating and scaling complex workflows and implementing processes for deployment in clinical laboratories at multiple sites. Involved in all aspects of assay automation development...|
|Functional Lead, Liquid Lifecycle Operations||Lab Operations||100328||San Diego||California||United States||San Diego, California, United States||Lab Operations||About the Job The Functional Lead provides leadership of all Lab Operations development related aspects of the representative Life Cycle team (LCTs). This position is accountable for the success of FMI’s portfolio from concept to commercializati...|
|Sr Dir, Early Research & Development||Research and Early Development||100108||San Diego||California||United States||San Diego, California, United States||Research and Early Development||About the Job The Senior Director leads the Early Research and Development department and leads systematic reviews of new technologies and biomarker candidates as well as assigned projects to addressing unmet needs in the oncology field. The pos...|
In June of 2020, we completed the acquisition of Lexent Bio, Inc., a precision oncology company located in California, developing novel multiomics liquid biopsy platforms to advance cancer care. This acquisition will accelerate our research and development strategy and expand its existing liquid biopsy platforms to advance cancer care for patients. The technology developed by Lexent Bio complements our existing efforts and partnerships aimed at developing advanced diagnostics for physicians, as well as genomically evaluating disease progression and informing treatment decisions at earlier stages of disease. Read more HERE.